Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating of “Buy” from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have received an average rating of “Buy” from the eight brokerages that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $11.60.

Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Thursday, May 1st. Wall Street Zen lowered Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. William Blair reiterated an “outperform” rating on shares of Immunic in a report on Friday, May 16th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Wednesday, June 25th. Finally, B. Riley reiterated a “buy” rating and set a $5.00 price target (down from $6.00) on shares of Immunic in a report on Friday, May 23rd.

Institutional Trading of Immunic

A number of large investors have recently bought and sold shares of IMUX. Invesco Ltd. acquired a new stake in Immunic during the 4th quarter worth about $37,000. Renaissance Technologies LLC increased its position in Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock valued at $567,000 after buying an additional 177,542 shares in the last quarter. Barclays PLC bought a new stake in Immunic in the 4th quarter valued at about $84,000. 683 Capital Management LLC increased its position in Immunic by 2.2% in the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after buying an additional 15,349 shares in the last quarter. Finally, Bridgeway Capital Management LLC increased its position in Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after buying an additional 22,200 shares in the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Stock Up 2.2%

Shares of NASDAQ:IMUX opened at $0.73 on Friday. The firm has a market cap of $69.85 million, a P/E ratio of -0.59 and a beta of 1.49. Immunic has a 12-month low of $0.56 and a 12-month high of $2.11. The business has a fifty day simple moving average of $0.87 and a 200 day simple moving average of $0.99.

Immunic (NASDAQ:IMUX) last announced its earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.25). As a group, equities research analysts expect that Immunic will post -0.94 EPS for the current year.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.